Építés alatt – nem éles oldal
Belépés
Résztvevőt keres itt: Kína1. fázis

Clinical Trial of CD19-targeted CAR-T Therapy for Refractory Juvenile Dermatomyositis

A legfontosabb adatok

Ki végzi
Chongqing Precision Biotech Co., Ltd
Hol
Hangzhou (Kína)A helyszín megnézése
Azonosító
Állapot
Toboroz
Fázis
1. fázis
Résztvevők
10 fő, tervezett
Kezdés
2024. júl. 2.
Várható befejezés
2028. júl. 31.
A vizsgálat típusa
Beavatkozással járó
A vizsgált kezelések
  • CD19-targetd CAR-T
A regiszteradat frissítve
2024. augusztus 26.

Ki vehet részt

MI-összefoglaló

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

The trial is looking for children and teens with juvenile dermatomyositis (JDM) that has not responded to usual treatment. They will receive CD19-targeted CAR-T cell therapy.

Életkor
5 years up to under 17 years.
Nem
All sexes can join.
A betegség stádiuma
Refractory JDM: the disease did not respond to, or was not tolerated with, standard treatment. Also at least one of these: fast-moving disease or disease in the lungs, heart or gut; calcium deposits under the skin, in muscles or joints; or rashes or skin ulcers that keep coming back. People with SRP or HMGCR antibody-positive immune-mediated necrotizing myopathy can also join. Heart, kidney, liver and lung function must be basically normal.
Korábbi kezelés
Must have had glucocorticoids (steroids) and at least 2 immunosuppressant drugs for at least 6 months, without enough benefit or with intolerance. Must not have had CAR T cell therapy before.
Biomarker vagy leletérték
A positive myositis-specific antibody test, such as MDA-5, NXP2, TIF-1γ or Ro-52. LVEF ≥55%, eGFR≥30ML/min/1.73m2, AST and ALT≤3.0 ULN, total bilirubin ≤2.0×ULN, SpO2≥92%.

A részvétel fő kizáró okai

  • Previous CAR T cell therapy.
  • Another autoimmune or rheumatic disease besides JDM, or a serious immune deficiency.
  • Serious or active infection, such as tuberculosis, hepatitis B or C, HIV, syphilis or CMV.
  • Cancer now or in the past, except removed skin basal cell carcinoma.
  • Serious heart problems, an organ or stem cell transplant within 3 months, or a positive pregnancy test.

A regiszter feltételei, szó szerint

Mind a 24 feltétel megnézéseKevesebb

Ki vehet részt

  • Age: ≥5 years and <17 years old
  • To meet the diagnostic criteria of JDM, four or five of the following criteria must be met:① symmetrical proximal muscle weakness; ②Characteristic skin changes, including positive dermatitis (purplish red rash on upper eyelid with periorbital edema) and Gottron papules (red patchy squamous papules on the back of knuckles); ③ The level of one muscle enzyme in serum was increased; ④ Positive myositis antibody; ⑤Electromyography shows denervation and myopathy; ⑥ Muscle biopsies showed necrosis and inflammation
  • The classification criteria of RJDM must meet ① and any of the criteria②-④: ① Patients who are intolerant or unresponsive to glucocorticoids and at least 2 immunosuppressants, adequate hormone therapy and duration of at least 6 months; ② The disease progresses rapidly and/or involves organs such as lungs, heart and gastrointestinal tract; ③ Calcification of subcutaneous or muscle and joint tissues; ④ Repeated rashes or skin ulcers
  • myositis specific antibody positive, defined as MDA-5, NXP2, TIF-1γ, Ro-52 and any other positive
  • If the patient has SRP or HMGCR antibody positive immune-mediated necrotizing myopathy equivalent to RJDM, the inclusion criteria of (2) - (4) can be met
  • The functions of important organs are basically normal:; ① Cardiac function: left ventricular ejection fraction (LVEF) ≥55%, no obvious abnormality in electrocardiogram; ② Renal function: eGFR≥30ML/min/1.73m2; ③ Liver function: AST and ALT≤3.0 ULN, total bilirubin ≤2.0×ULN; ④ Lung function: Lung function is basically normal, SpO2≥92%
  • Have the criteria for simple or intravenous blood collection, and no other contraindications for cell collection
  • The subject of childbearing age has a negative urine pregnancy test result and agrees to take effective contraceptive measures during the test period until 1 year after the infusion
  • The patient or his/her guardian agrees to participate in this clinical trial and signs an informed consent indicating that he/she understands the purpose and procedure of this clinical trial and is willing to participate in the study

Ki nem vehet részt

  • Had previously received CAR T cell therapy
  • Congenital heart disease or history of acute myocardial infarction within 6 months before screening, or severe arrhythmias (including multi-source frequent supraventricular tachycardia, ventricular tachycardia, etc.); Or combined with a large number of pericardial effusion, serious myocarditis, etc.; Or patients with unstable vital signs who need hypertensive drugs to maintain their blood pressure
  • There is an active or uncontrollable infection that requires systemic treatment within 1 week prior to screening
  • Received solid organ transplantation or hematopoietic stem cell transplantation within 3 months before screening; Acute graft-versus-host disease (GVHD) of grade 2 or above was present within 2 weeks prior to screening
  • Had received live vaccine within 4 weeks prior to screening
  • Patients who had participated in other clinical trials within 3 months prior to enrollment
  • Have other autoimmune or rheumatic diseases other than JDM
  • accompanied by serious infectious diseases, including but not limited to active tuberculosis, latent tuberculosis infection, active viral hepatitis, etc
  • Evidence of active malignant disease or diagnosis of malignant tumor (including hematological malignancies and solid tumors, except resected and cured skin basal cell carcinoma)
  • suffering from other diseases that require long-term use of glucocorticoids or immunosuppressants
  • Hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) positive and peripheral blood hepatitis B virus (HBV) DNA titer greater than the normal reference value range; Or hepatitis C virus (HCV) antibody positive and peripheral blood hepatitis C virus (HCV) RNA titer greater than the normal reference value range; Or positive for human immunodeficiency virus (HIV) antibodies; Or syphilis test positive; Or cytomegalovirus (CMV) DNA test positive
  • Patients with known malignant diseases such as tumors before screening
  • primary immunodeficiency or severe secondary immunodeficiency that has not been corrected
  • Positive blood pregnancy test
  • Situations in which other investigators consider it inappropriate to participate in the study

Nézd meg, megfelelhetsz-e

Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.

  • 5 és 17 év között vagy?

Helyszínek itt: Kína

  • Children's Hospital, Zhejiang University School of MedicineHangzhou, KínaContact: Meiping Lu, M.DRésztvevőt keres

A vizsgálatról

Mit akar kideríteni a vizsgálat

This is a Phase I clinical trial to evaluate the efficacy and safety of CD19-targeted CAR-T in the treatment of refractory juvenile dermatomyositis (RJDM).The experiment was divided into two phases: dose exploration (Part A) and dose extension (Part B).

A vizsgálat csoportja

  • CD19-targeted CAR-TA vizsgált kezelés

    The experiment was divided into two phases: dose exploration (Part A) and dose extension (Part B).

    Kezelés: CD19-targetd CAR-T

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
Clinical Study of CD19 Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of Refractory Juvenile Dermatomyositis (RJDM)
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
Illeszkedési kérdések
Forrás: NCT06569472: ki vehet részt
A regiszteradat frissítve
2024. augusztus 26.